Education
About Us
Working with TipRanks
Follow Us
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$6.68M
Enterprise ValueAU$6.09M
Total Cash (Recent Filing)AU$250.99K
Total Debt (Recent Filing)AU$200.00K
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Feb 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding53,433,330
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Profit MarginA high gross profit margin indicates the company's core products or services have strong unit economics. That provides durable leverage to restore profitability if operating expenses are cut or revenue stabilizes, supporting recovery potential over the next 2–6 months.
Structural Industry ExposureBeing in the biotechnology sector offers structural tailwinds from sustained demand for innovation, therapies, and diagnostics. This industry positioning gives the company long-term market opportunity if it can secure funding and execute development or commercialization plans.
Reported EPS ImprovementReported EPS growth of ~24% suggests improvement in per-share profitability, reflecting operational or mix progress. If this trend continues, it signals improving efficiency or margins and can underpin better cash generation and capital access over the medium term.
Bears Say
Severe Revenue DeclineA nearly 46% year decline in revenue denotes meaningful demand loss or commercial setbacks. Such steep top-line deterioration erodes operating leverage, stresses margins, and requires substantial strategy or product changes to re-establish sustainable growth within months.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the company cannot self-fund operations or investments. This structural cash shortfall raises refinancing or dilution risk and constrains R&D, commercialization, and strategic flexibility over the coming 2–6 months.
Distressed Balance SheetNegative shareholder equity and a negative debt-to-equity ratio reflect financial distress and high leverage. This weak capital structure limits borrowing capacity, increases insolvency risk, and hampers the company's ability to fund operations or invest for recovery in the medium term.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$6.68M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Feb 20, 2026 which is in 15 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.013.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,433,330 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
-289.05%
Trailing 12-Months
Asset Growth
-61.36%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.